Compugen (CGEN) News Today $1.45 +0.07 (+5.07%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Head-To-Head Comparison: Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) vs. Compugen (NASDAQ:CGEN)April 13 at 1:54 AM | americanbankingnews.comCompugen to Participate in Multiple Virtual Investor Conferences in April 2025March 26, 2025 | prnewswire.comCompugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comCompugen (NASDAQ:CGEN) Cut to "Hold" at StockNews.comStockNews.com lowered shares of Compugen from a "buy" rating to a "hold" rating in a research note on Wednesday.March 6, 2025 | marketbeat.comCalculating The Intrinsic Value Of Compugen Ltd. (NASDAQ:CGEN)March 6, 2025 | uk.finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | insidermonkey.comCompugen reports Q4 EPS (7c) vs. 11c last yearMarch 4, 2025 | markets.businessinsider.comCompugen Ltd. (CGEN) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comCompugen (NASDAQ:CGEN) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPSCompugen (NASDAQ:CGEN - Get Free Report) issued its earnings results on Tuesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.14). Compugen had a net margin of 2.67% and a return on equity of 2.62%.March 4, 2025 | marketbeat.comCompugen Reports Fourth Quarter and Full Year 2024 ResultsMarch 4, 2025 | prnewswire.comCompugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare ConferenceMarch 3, 2025 | prnewswire.comCompugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing TechnologyFebruary 26, 2025 | prnewswire.comCompugen (CGEN) Projected to Post Quarterly Earnings on TuesdayCompugen (NASDAQ:CGEN) will be releasing earnings before the market opens on Tuesday, March 4. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=667255)February 25, 2025 | marketbeat.comCompugen Ltd. Sets Date for Q4 2024 Financial Results AnnouncementFebruary 18, 2025 | tipranks.comCompugen: Immuno-Oncology Innovator Poised For A ComebackFebruary 18, 2025 | seekingalpha.comCompugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025February 18, 2025 | prnewswire.comCompugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving Average - Time to Sell?Compugen (NASDAQ:CGEN) Share Price Crosses Above 200-Day Moving Average - Here's WhyFebruary 18, 2025 | marketbeat.comCompugen Ltd. (CGEN) Stock Price, News, Quote & History - Yahoo FinanceFebruary 9, 2025 | finance.yahoo.comCompugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | prnewswire.comJPMorgan Chase & Co. Has $122,000 Holdings in Compugen Ltd. (NASDAQ:CGEN)JPMorgan Chase & Co. trimmed its position in Compugen Ltd. (NASDAQ:CGEN - Free Report) by 62.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,485 shares of the biotechnology company's stock after selling 113,287 shaFebruary 3, 2025 | marketbeat.comCompugen Ltd. (CGEN.TA)January 30, 2025 | ca.finance.yahoo.comCompugen (NASDAQ:CGEN) Share Price Passes Above 200 Day Moving Average - Here's WhyCompugen (NASDAQ:CGEN) Shares Pass Above 200 Day Moving Average - Should You Sell?January 29, 2025 | marketbeat.comCompugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?Compugen (NASDAQ:CGEN) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?January 21, 2025 | marketbeat.comOppenheimer Reaffirms Their Buy Rating on Compugen (CGEN)January 14, 2025 | markets.businessinsider.comCompugen initiated with an Outperform at OppenheimerJanuary 13, 2025 | markets.businessinsider.comCompugen (NASDAQ:CGEN) Earns Outperform Rating from Analysts at OppenheimerOppenheimer began coverage on shares of Compugen in a research note on Monday. They set an "outperform" rating and a $4.00 price objective on the stock.January 13, 2025 | marketbeat.comCompugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsJanuary 8, 2025 | prnewswire.comCompugen Ltd.January 3, 2025 | wsj.comThe past five years for Compugen (NASDAQ:CGEN) investors has not been profitableDecember 26, 2024 | uk.finance.yahoo.comCompugen Bolsters Cancer Therapy Portfolio with New PatentNovember 28, 2024 | markets.businessinsider.comCompugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesNovember 27, 2024 | prnewswire.comRoche anti-TIGIT therapy fails to extend survival in late-stage lung cancer trialNovember 26, 2024 | msn.comCompugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in OctoberCompugen Ltd. (NASDAQ:CGEN - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,270,000 shares, a decrease of 18.1% from the October 15th total of 1,550,000 shares. Based on an average trading volume of 225,400 shares, the days-to-cover ratio is currently 5.6 days.November 16, 2024 | marketbeat.comCompugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?November 16, 2024 | finance.yahoo.comCompugen’s Financial Surge and Promising Drug TrialsNovember 14, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Compugen (CGEN)November 14, 2024 | markets.businessinsider.comCompugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comCompugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...November 13, 2024 | finance.yahoo.comCompugen Ltd. (CGEN) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comCompugen Ltd.: Compugen Reports Third Quarter 2024 ResultsNovember 12, 2024 | finanznachrichten.deCompugen Reports Third Quarter 2024 ResultsNovember 12, 2024 | prnewswire.comCompugen to Participate in Stifel 2024 Healthcare ConferenceNovember 11, 2024 | prnewswire.comCompugen (CGEN) Receives a Buy from Stifel NicolausNovember 7, 2024 | markets.businessinsider.comCompugen (CGEN) to Release Earnings on TuesdayCompugen (NASDAQ:CGEN) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=641326)November 5, 2024 | marketbeat.comCompugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024November 5, 2024 | prnewswire.comShort Interest in Compugen Ltd. (NASDAQ:CGEN) Decreases By 17.1%Compugen Ltd. (NASDAQ:CGEN - Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 1,550,000 shares, a decrease of 17.1% from the September 30th total of 1,870,000 shares. Based on an average daily trading volume, of 231,800 shares, the short-interest ratio is currently 6.7 days.October 29, 2024 | marketbeat.comCompugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024October 29, 2024 | prnewswire.comCompugen to Present New Clinical Data at SITC 2024October 7, 2024 | prnewswire.comBiomerica (NASDAQ:BMRA) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comCompugen Ltd. (NASDAQ:CGEN) Sees Large Growth in Short InterestCompugen Ltd. (NASDAQ:CGEN - Get Free Report) saw a large growth in short interest in September. As of September 15th, there was short interest totalling 1,880,000 shares, a growth of 15.3% from the August 31st total of 1,630,000 shares. Based on an average daily volume of 256,200 shares, the days-to-cover ratio is currently 7.3 days.September 29, 2024 | marketbeat.com Remove Ads Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Media Mentions By Week CGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEN News Sentiment▼0.930.79▲Average Medical News Sentiment CGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEN Articles This Week▼11▲CGEN Articles Average Week Remove Ads Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CorMedix News Sage Therapeutics News Cullinan Therapeutics News Maravai LifeSciences News Tyra Biosciences News SIGA Technologies News Relay Therapeutics News Akebia Therapeutics News MeiraGTx News Mind Medicine (MindMed) News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGEN Stock Free CGEN Stock Alerts